Skeletal Alkaline Phosphatase in
the Metastatic Workup of Patients
with Prostate Cancer

Jm, Wolff; Ittel, T. H.; Boeckmann, W.; Reinike, T; Fk, Habib; Jakse, G.

doi:10.1159/000474187

Cited by 10 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in agreement with those in the literature [13,14]. Elevated PSA levels were however found in the group of localized PCa.…”

Section: Discussionsupporting

confidence: 93%

“…It is possible to discriminate between localized and advanced PCa. Wolff et al [ 13] corresponding sensitivity and spccifity for PSA (cutoff M() vs. M| >100 ng/ml) of 65 and 73%, and for sAP (cutoff Mo vs. Mt > 19 pg/1) of 65 and 100%. These results suggest that sAP could become a useful additional marker to dif ferentiate between localized and advanced PCa.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Skeletal Alkaline Phosphatase: A Marker for Individual Follow-Up in Patients with Advanced Prostatic Cancer

1997

View full text Add to dashboard Cite

Skeletal alkaline phosphatase (sAP) is a tumor marker indicating osseous metastases, e.g. of prostate cancer. Sera of healthy men and patients with benign prostatic hyperplasia (BPH), localized and advanced prostatic cancer (PCa) were analyzed with Tandem-R-Ostase® and prostate-specific antigen (PSA). No significant differences were found in sAP levels between healthy men and patients with BPH and localized PCa, but there was a significant difference with the group of patients with advanced PCa. In some cases, the individual follow-up was better and earlier with sAP compared to PSA. It is possible to discriminate between localized and advanced PCa with sAP. The individual follow-up shows in 30% of patients with advanced PCa an earlier increase in sAP, compared to PSA, during progression of disease.

show abstract

“…These results are in agreement with those in the literature [13,14]. Elevated PSA levels were however found in the group of localized PCa.…”

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Skeletal Alkaline Phosphatase: A Marker for Individual Follow-Up in Patients with Advanced Prostatic Cancer

1997

View full text Add to dashboard Cite

show abstract

“…This is in contrast to earlier reports that collectively grouped all bone scans vs. total PSA results, based only on initial evaluation [18,19]. As noted previously, this is not due to patient selection bias, as our group composition was similar to those reported previously [7,8,18,19]. Total alkaline phosphatase or bone alkaline phosphatase, based on ROC cutoff values (>.75), were discriminatory beyond >6 lesions in the quantified bone scan series (Tables II and III, Fig.…”

Section: Discussioncontrasting

confidence: 76%

“…A number of patients had had a prior radical prostatectomy, which affected in part the postoperative total and free PSA levels. This entire group of patients was compared to the others reported in terms of the findings of positive or negative bone scans, and was found to be similar (pairwise Pearson correlation coefficient values >.95) [7,8,[15][16][17][18][19]. Table II describes the average values of the 70 patients for the individual 2-3-serum measurements obtained during the test period with regard to bone scan category.…”

Section: Methodsmentioning

confidence: 93%

Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer

et al. 1997

View full text Add to dashboard Cite

“…Our pilot study in 39 patients provided preliminary evidence that SAP is a useful marker for bone metastases in patients with untreated CaP [11]. These findings prompted us to evaluate the usefulness of SAP and PSA levels in the diagnosis of bone metastases in a larger series of 73 patients with newly diagnosed CaP.…”

Section: Skeletal Alkaline Phosphatase and Prostate Cancermentioning

confidence: 85%

Efficacy of Skeletal Alkaline Phosphatase and Prostate-Specific Antigen in the Diagnosis of Bone Metastasis in Cancer of the Prostate

Wolff¹,

Ittel

Borchers³

et al. 1998

Urol Int

Self Cite

View full text Add to dashboard Cite

Purpose: To study the efficacy of prostate-specific antigen (PSA) and skeletal alkaline phosphatase (SAP) as staging markers in discriminating patients with cancer of the prostate (CaP) with (M+) and without bone metastases (M0). Material and Methods: 73 patients with untreated CaP entered the study. After staging the patients were divided into 3 groups: group I, patients with CaP and bone metastases (n = 21); group II, patients with locally advanced CaP without bone metastases (n = 26), and group III, patients with clinically localized CaP without bone metastases (n = 26). Results: None of the M0 patients but 71% of the M+ patients exhibited an increased SAP. A corresponding cutoff point of 100 ng/ml for PSA showed that 19% of M0 patients and 71% of the M+ patients exhibited a value of >100 ng/ml. This resulted in a sensitivity and specificity of 71 and 100% of SAP and 71 and 81% for PSA, respectively. Conclusion: SAP could become a useful marker in the evaluation of patients with newly diagnosed CaP as it provides additional information concerning the skeletal status of these patients.

show abstract

Skeletal Alkaline Phosphatase in the Metastatic Workup of Patients with Prostate Cancer

Cited by 10 publications

References 13 publications

Skeletal Alkaline Phosphatase: A Marker for Individual Follow-Up in Patients with Advanced Prostatic Cancer

Skeletal Alkaline Phosphatase: A Marker for Individual Follow-Up in Patients with Advanced Prostatic Cancer

Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer

Efficacy of Skeletal Alkaline Phosphatase and Prostate-Specific Antigen in the Diagnosis of Bone Metastasis in Cancer of the Prostate

Contact Info

Product

Resources

About